Despite the central roles and high frequencies of PI3K, MAPK, and p53 pathway dysregulation in human cancer, it is remarkable how little clinical efficacy has been achieved with single agents targeting each of these axes [16-18, 39, 40]. This evidence concerns the gene TP53 and cancer.